key: cord-0943274-j6qa5eco authors: Richardson, Simone I.; Madzorera, Vimbai Sharon; Spencer, Holly; Manamela, Nelia P.; van der Mescht, Mieke A.; Lambson, Bronwen E.; Oosthuysen, Brent; Ayres, Frances; Makhado, Zanele; Moyo-Gwete, Thandeka; Mzindle, Nonkululeko; Motlou, Thopisang; Strydom, Amy; Mendes, Adriano; Tegally, Houriiyah; de Beer, Zelda; Roma de Villiers, Talita; Bodenstein, Annie; van den Berg, Gretha; Venter, Marietjie; de Oliviera, Tulio; Ueckermann, Veronica; Rossouw, Theresa M.; Boswell, Michael T.; Moore, Penny L. title: SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals date: 2022-03-25 journal: Cell Host Microbe DOI: 10.1016/j.chom.2022.03.029 sha: e902961fb1673fe4d26ee13a90e0c83c61fa71f2 doc_id: 943274 cord_uid: j6qa5eco The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses to other variants of concern (VOCs) remains unknown. We use plasma from 20 unvaccinated and seven vaccinated individuals infected by Omicron BA.1 to test binding, Fc effector function and neutralization against VOCs. In unvaccinated individuals, Fc effector function and binding antibodies target Omicron and other VOCs at comparable levels. However, Omicron BA.1-triggered neutralization is not extensively cross-reactive for VOCs (14 to 31-fold titer reduction) and we observe 4-fold decreased titers against Omicron BA.2. In contrast, vaccination followed by breakthrough Omicron infection associates with improved cross-neutralization of VOCs, with titers exceeding 1:2,100. This has important implications for vulnerability of unvaccinated Omicron-infected individuals to reinfection by circulating and emerging VOCs. While Omicron-based immunogens may be adequate boosters, they are unlikely to be superior to existing vaccines for priming in SARS-CoV-2 naïve individuals. Omicron infection Omicron BA.2 Increased activity J o u r n a l P r e -p r o o f The emergence of the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VOC) in November 2021 coincided with the fourth wave of South Africa's COVID-19 epidemic (Viana et al., 2022) . Omicron is defined by multiple mutations across its genome, including more than 30 mutations in spike, many of which are associated with immune evasion (Viana et al., 2022) . Omicron has further evolved in additional sub-lineages, including BA.1 and BA.2, with 17 amino acid, 3 deletions and one insertion distinguishing the two sub-lineages, many in the N terminal domain (NTD) and receptor binding domain (RBD). These mutations confer neutralization escape in vaccinees and in donors previously infected with other variants (Cele et al., 2021; Garcia-Beltran et al., 2022; Schmidt et al., 2021; Sievers et al., 2022) . In contrast to neutralization, antibody binding to the Omicron variant is preserved, as observed for other VOCs (Carreño et al., 2021; Wibmer et al., 2021) . Although Fc receptor binding was substantially reduced in antibodies tested against Omicron (Bartsch et al., 2021) , functional Fc effector responses have not yet been reported. The ability of antibodies to bind the Omicron spike suggests that cytotoxic effector functions driven by antibodies may also be retained, as for earlier VOCs (Kaplonek et al., 2022; Richardson et al., 2022) . This, along with the finding that T cells triggered by infection or vaccination are cross-reactive for Omicron (Gao et al., 2022; Keeton et al., 2022; Tarke et al., 2022) , likely contributes to maintained vaccine effectiveness against severe disease following Omicron infection (Collie et al., 2022) . While there is substantial data showing that Omicron evades neutralizing ]responses, little is known about the humoral response that Omicron infection itself triggers. Defining the capacity of Omicron to trigger cross-reactive binding, neutralizing and Fc effector responses antibodies will inform its potential to protect from reinfection by currently circulating or emerging VOCs. This is of particular relevance for developing countries such as South Africa, where vaccination levels are low and genomic surveillance indicates continued J o u r n a l P r e -p r o o f circulation of Delta and other variants. Furthermore, little is known about the activity of antibodies triggered by BA.1 infection against BA.2 (Yamasoba et al., 2022; Yu et al., 2022) . Secondly, these data inform the potential immunogenicity of Omicron-based vaccines under development by several companies. Plasma from individuals infected in the fourth wave of COVID-19 pandemic in South Africa The median ages of the vaccinated and unvaccinated individuals were similar (58 and 64 respectively), and infections ranged from mild to severe as determined by WHO scoring (Table S1) . We first compared binding antibody levels, as measured by enzyme-linked immunosorbent Figure 1B , C). Furthermore, antibodies from these vaccinated individuals exhibited higher levels of cross-reactivity against all variants, and no significant fold losses were observed ( Figure 1B ). As spike binding antibodies perform Fc effector functions known to contribute to reduced disease severity and vaccine efficacy (Yu et al., 2020; Zohar et al., 2020) , we examined antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) in both groups. For unvaccinated individuals, ADCP against Omicron BA.1 was detected in all 20 individuals with a geometric mean (GM) score of 32 ( Figure 1D ). Against VOCs, we observed less than two-fold reduction in activity across variants with 15%, 25% and 10% of individuals losing ADCP activity against D614G, and Beta and Delta respectively. For vaccinated individuals, non-significant reductions against D614G, Beta and Delta were observed relative to Omicron BA.1 and all donors exhibited activity against the panel of VOC tested here ( Figure 1E ). Compared to unvaccinated individuals, significantly higher levels of ADCP were observed in vaccinated individuals infected with Omicron BA.1, mirroring the binding antibodies ( Figure 1E , F). In contrast to binding and ADCP, ADCC in unvaccinated individuals showed significant losses against D614G (3-fold loss) and Beta (4-fold loss). However, like ADCP and binding antibodies, ADCC activity against Delta was retained ( Figure 1G ). In this group, Omicron BA.1-triggered ADCC was undetectable against D614G and Beta in 25% and 30% of plasma samples, respectively. After previous vaccination, Omicron BA.1 breakthrough infections resulted in overall preservation of ADCC against VOCs, with only one individual showing undetectable activity against Delta ( Figure 1H ). Levels of ADCC in previously vaccinated donors were significantly higher than those in unvaccinated individuals, except for Delta, where similar ADCC activity was observed in both groups ( Figure 1I ). Lastly, we measured neutralizing antibody responses to Omicron BA.1, and assessed crossreactivity for VOCs. In addition to the variants used above, we also tested C.1.2, a variant with several neutralization evasive mutations, which circulated at low levels during the third and fourth COVID-19 waves in South Africa Figure S1A and B). Similarly, samples from BNT162b2 or Ad26.COV2.S showed higher activity against D614G than Omicron (Supplementary Figure 1A and B), consistent with previous studies (Cele et al., 2021; Garcia-Beltran et al., 2022) . We and others have shown that Fc effector function is largely preserved against VOCs in both convalescent and vaccine-elicited plasma (Kaplonek et al., 2022; Richardson et al., 2022) . Also, as with neutralization, we have shown that Fc effector function triggered by Beta is more cross-reactive compared to antibodies elicited by D614G, indicating that the spike sequence of the eliciting immunogen impacts the extent of ADCC cross-reactivity (Moyo- Gwete et al., 2021; Richardson et al., 2022) . Here, we show that Omicron infection similarly triggers differential ADCC cross-reactivity, with significantly decreased activity against D614G and Beta, but not Delta. This observation extended to vaccinated individuals, where ADCC was still significantly poorer against Beta. This differential targeting of ADCCmediating antibodies indicates that they may preferentially bind sites that differ between Omicron and other VOCs. Alternatively, different VOCs may trigger antibodies with varied glycosylations and isotype, both of which modulate Fc effector function (Jennewein and Alter, 2017). This differential immune imprinting by VOCs was also confirmed for neutralization in this study in both unvaccinated and vaccinated Omicron-infected individuals. The highest titers in unvaccinated individuals were to the infection-matched Omicron. In contrast, in previously vaccinated individuals with breakthrough Omicron infections, high titers were observed against both D614G and Omicron; sequences that match the vaccine and infecting spikes to which these donors have been exposed. This is consistent with our studies of immune responses triggered by D614G, Beta or Delta (Keeton et al., 2021; Moyo-Gwete et al., 2021; Wibmer et al., 2021) which resulted in distinct patterns of cross-reactivity compared to those observed here after Omicron infection. Together these data indicate that the sequence of the infecting spike impacts the quality of neutralization, suggesting imprinting of the immune response (Keeton et al., 2021) . We and others have shown that humoral function is significantly boosted in individuals with breakthrough infections after vaccination (Kitchin et al., 2022; Suryawanshi et al., 2022; Walls et al., 2022) . This study confirms this is also true of Omicron breakthrough infections, with a 153-fold increase in titers to D614G in vaccinated compared to unvaccinated individuals, consistent with other studies (Khan et al., 2022; Suryawanshi et al., 2022; Zhou et al., 2022) . We also extend our previous study, where we showed ADCC was boosted by breakthrough infection, to include ADCP, confirming that this applies to other Fc effector functions (Kitchin et al., 2022) . In the absence of vaccination, Omicron- Our data also have implications for the design of second-generation vaccines based on Omicron, suggesting these may not trigger cross-reactive de novo responses in SARS-CoV-2 naive individuals. This is supported by immunogenicity studies, where Delta-infected mice elicited broadly protective antibodies, but Omicron-infected mice failed to mount responses against other VOCs (Suryawanshi et al., 2022) . In addition, immunization of mice with a receptor binding domain (RBD)-based Omicron mRNA vaccine only elicited strain-specific neutralization (Lee et al., 2022) . In support of this study and others (Hawman et al., 2022) , our data also suggests that Omicron is highly immunogenic, eliciting comparable neutralization titers irrespective of vaccination status but through a largely strain-specific response. Given the significantly higher titers we see against Omicron in vaccinated individuals, Omicron boosters may be effective in seropositive individuals, a group that exceeds 70% in South Africa (Madhi et al., 2022) . However, in a comparison of mRNA-1273 vaccinated rhesus macaques boosted with either mRNA-Omicron or mRNA-1273, Omicron boosted animals showed lower titers than those with a homologous mRNA-1273 boost (Gagne et al., 2022) . Overall, these data suggest that boosting individuals with or without immunity with vaccines specific for Omicron is unlikely to be superior to existing regimens. Our study is limited by the fact that we cannot rule out prior asymptomatic infection which could alter the quality of humoral responses. Sampling for this study was limited to blood, and occurred early in infection when antibodies may not have reached peak cross-reactivity. sequencing. PLM conceptualized the study and wrote the manuscript. All authors declare no competing interests. Further information and reasonable requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Penny Moore (pennym@nicd.ac.za). Materials will be made by request to Penny Moore (pennym@nicd.ac.za). · All data reported in this paper will be shared by the lead contact upon request. · This paper does not report original code. · Any additional information required to reanalyze the data reported in this paper is available from the Lead Contact upon request. KewalRamani. Cells were cultured at 37°C, 5% CO2 in RPMI containing 10% heatinactivated fetal bovine serum (Gibco, Gaithersburg, MD) with 1% Penicillin Streptomycin (Gibco, Gaithersburg, MD) and 2-mercaptoethanol to a final concentration of 0.05 mM and not allowed to exceed 4 x 10 5 cells/ml to prevent differentiation. Sequencing of the spike was performed as previously described using swabs obtained from Tshwane District Hospital patients of which 6 were available and confirmed to be Omicron BA.1 (Table S1 ). RNA sequencing was performed as previously published. Briefly, extracted RNA was used to synthesize cDNA using the Superscript IV humidity and 10% CO2, proteins were first purified using a nickel resin followed by sizeexclusion chromatography. Relevant fractions were collected and frozen at -80 °C until use. Two μg/ml of spike protein (D614G, Beta, Delta or Omicron) was used to coat 96-well, highbinding plates and incubated overnight at 4 °C. The plates were incubated in a blocking buffer consisting of 5% skimmed milk powder, 0.05% Tween 20, 1x PBS. Plasma samples were diluted to 1:100 starting dilution in a blocking buffer and added to the plates. IgG secondary antibody was diluted to 1:3000 in blocking buffer and added to the plates followed by TMB substrate (Thermofisher Scientific). Upon stopping the reaction with 1 M H2SO4, absorbance was measured at a 450nm wavelength. In all instances, mAbs CR3022 and BD23 were used as positive controls and Palivizumab was used as a negative control. (HIV-1 pNL4.luc) plasmid as previously described . Culture supernatants were clarified of cells by a 0.45-μM filter and stored at −70 °C. Other pcDNA plasmids were used for the ADCC assay. For the neutralization assay, plasma samples were heat-inactivated and clarified by centrifugation. Heat-inactivated plasma samples from vaccine recipients were incubated with the SARS-CoV-2 pseudotyped virus for 1 hour at 37°C, 5% CO2. Subsequently, 1x10 4 HEK293T cells engineered to over-express ACE-2 (293T/ACE2.MF)(kindly provided by M. Farzan (Scripps Research)) were added and incubated at 37°C, 5% CO2 for 72 hours upon which the luminescence of the luciferase gene was measured. Titers were calculated as the reciprocal plasma dilution (ID50) causing 50% reduction of relative light units. CB6 and CA1 was used as positive controls for D614G, Beta and Delta. 084-7D, a mAb targeting K417N was used as a positive control for Omicron and Beta. Avitagged SARS-CoV-2 spikes were biotinylated using the BirA biotin-protein ligase standard reaction kit (Avidity, LLC) and coated onto fluorescent neutravidin beads as previously described (Ackerman et al., 2011) . Briefly, beads were incubated for two hours with monoclonal antibodies at a starting concentration of 20 μg/ml or plasma at a single 1 in 100 dilution. Opsonized beads were incubated with the monocytic THP-1 cell line overnight, fixed and interrogated on the FACSAria II. Phagocytosis score was calculated as the percentage of THP-1 cells that engulfed fluorescent beads multiplied by the geometric mean fluorescence intensity of the population less the no antibody control. For this and all subsequent Fc effector assays, pooled plasma from 5 PCR-confirmed SARS-CoV-2 infected individuals and CR3022 were used as positive controls and plasma from 5 pre-pandemic healthy controls and Palivizumab were used as negative controls. 084-7D was used as a positive control for Omicron BA.1 and Beta. In addition samples both waves were run headto-head in the same experiment. ADCP scores for different spikes were normalised to each other and between runs using CR3022. The ability of plasma antibodies to cross-link and signal through FcγRIIIa (CD16) and spike expressing cells or SARS-CoV-2 protein was measured as a proxy for ADCC. For spike assays, HEK293T cells were transfected with 5μg of SARS-CoV-2 spike plasmids using PEI-MAX 40,000 (Polysciences) and incubated for 2 days at 37°C. Expression of spike was J o u r n a l P r e -p r o o f A robust, high-throughput assay to J o u r n a l P r e -p r o o f determine the phagocytic activity of clinical antibody samples Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron Ancestral SARS-CoV-2-specific T cells crossrecognize the Omicron variant Nextstrain: real-time tracking of pathogen evolution Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine The Immunoregulatory Roles of Antibody Glycosylation mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner T cell responses to SARS-CoV-2 spike crossrecognize Omicron Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants South African Population Immunity and Severe Covid-19 with Omicron Variant Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity Emergence and phenotypic characterization of C.1.2, a globally detected lineage that rapidly accumulated mutations of concern Plasma Neutralization of the SARS-CoV-2 Omicron Variant Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron Detection of a SARS-CoV-2 variant of concern in South Africa Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses V2 escapes neutralization by South African COVID-19 donor plasma Virological characteristics of SARS-CoV-2 BA.2 variant DNA vaccine protection against SARS-CoV-2 in rhesus macaques 1 and BA.2 Variants Vaccine-breakthrough infection by the SARS-CoV-2 omicron variant elicits broadly cross-reactive immune responses We acknowledge the participants who volunteered for this study and thank W van Hougenhouck-Tulleken and R Ramlall for database support and participant recruitment and D Amoako and J Giandhari for sequencing. The parental soluble spike was provided by J • Omicron infection elicits potent neutralizing and Fc effector antibody responses • Omicron triggered neutralizing antibodies are poorly cross-reactive for VOCs • Vaccination prior to infection increases antibody titers and cross reactivity • Omicron vaccines are unlikely to be superior to current vaccines in naïve individuals eTOC blurb Richardson et al. show that SARS-CoV-2 Omicron infection in unvaccinated individuals triggers potent antibody responses; however, cross-reactivity against variants of concern is poor. In contrast, Omicron BA.1 breakthrough infection in vaccinated individuals elicits high titer cross-reactive antibodies. Omicron-based vaccines are thus unlikely to be superior immunogens in SARS-COV-2 naïve individuals.